Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that can be removed by surgery (resectable) colorectal cancer. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab before surgery may make

Trial Details

NCT ID
NCT07595874
Phase
PHASE2
Sponsor
City of Hope Medical Center
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Balstilimab
  • Biospecimen Collection
  • Botensilimab
  • Computed Tomography
  • Magnetic Resonance Imaging
Locations (sample)
  • Goodyear, Arizona, United States|33.43532,-112.35821
  • Corona, California, United States|33.87529,-117.56644
  • Duarte, California, United States|34.13945,-117.97729
  • Huntington Beach, California, United States|33.6603,-117.99923
  • Irvine, California, United States|33.66946,-117.82311

Key Eligibility Criteria

  • Documented informed consent of the participant and Legally Authorized Representative (when applicable)
  • Assent, when appropriate, will be obtained and documented for adults lacking capacity per institutional guidelines
  • Agreement to allow the use of tissue from past and future surgery and standard of care biopsies
  • Age: ≥ 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →